Monday June 14, 1999
Company Press Release
Helix BioPharma Corp.
AURORA, ONTARIO--Isoprinosine=C6, an approved anti-viral pharmaceutical used to treat sub-acute sclerosing panencephalitis, has shown to be promising in the treatment of Chronic Fatigue Syndrome.
In a presentation made to the Neuro Immune Dysfunction Syndrome Medical Conference in Bethesda, Maryland, Dr. Byron Hyde of the Ottawa-based Nightingale Foundation described the results of his small clinical study into the treatment of patients with Isoprinosine=C6 versus a placebo. His study demonstrated that Isoprinosine=C6 appears to relieve the symptoms of this debilitating condition in some patients.
``I am happy with the results of our preliminary study of the treatment of chronic fatigue patients with Isoprinosine=C6. I believe that this is a safe medication with the promise of improvement of the quality of life for some CFS patients,'' stated Dr. Hyde, ``Some patients may even be able to return to work.''
Isoprinosine=C6 is distributed in Canada exclusively by Helix BioPharma Corp.'s subsidiary, Rivex Pharma Inc.
Approximately 500,000 people in North America are estimated to suffer from Chronic Fatigue Syndrome, many of whom are unable to work due to the profound tiredness associated with the disorder. Patients typically function at levels of activity substantially lower than their capacity before the onset of illness and may become exhausted with only light physical activity.
The cause of Chronic Fatigue Syndrome has not been identified.
Isoprinosine=C6 is a registered trademark of Newport Pharmaceuticals Ltd.
Information contained in this news release includes forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially.
Helix BioPharma trades on the TSE under the symbol ``HBP''
Any comments? Send them to Bill Jackson at email@example.com
Back to CFS Index Page